Novitero
Download Novitero.pdf
Cancer cells constantly undergo genomic changes (i.e. mutations), which allow them to escape from the body’s defense mechanisms and from targeted drugs, and enables them to continue to divide and spread. Despite the availability of selected second and third line targeted therapies, cancer evolution is expected to prevail and to ultimately result in resistance and treatment failure. Novitero’s innovation lies in the prediction of those changes and in the design and development of new structurally adapted drugs to a priory bypass these upcoming mutations, using unique computer-based technologies and algorithms.
The growing market for small molecule targeted cancer drugs exceeds 20 billion dollar yearly. However, evolving resistances that will hinder the long-term effectiveness of these drugs have been described for all small molecule targeted cancer drugs. The company answers an immense and growing need of combating these resistances with the potential to provide enduring solution for many patients in various cancer types.
Copyright © 2024